This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why You Should Hold Onto Neogen (NEOG) Stock Now
by Zacks Equity Research
Investors' trust continues to be high in Neogen (NEO), thanks to strength in its Food Safety and Genomic businesses.
Penumbra, Lovesac, Netflix, NBCUniversal and Amazon highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Penumbra, Lovesac, Netflix, NBCUniversal and Amazon highlighted as Zacks Bull and Bear of the Day
TFX or STE: Which is a Better Investment Pick Right Now?
by Zacks Equity Research
STERIS (STE) scores higher than Teleflex (TFX) when it comes to valuation and one-year price performance.
Bull of the Day: Penumbra (PEN)
by Kevin Cook
This $6 billion innovator removes blood clots and the deadly shadow of stroke with catheter-based aspiration technologies
Illumina (ILMN) Grows on Innovation & International Growth
by Zacks Equity Research
Illumina (ILMN) is benefiting from sturdy demand for sequencing and array systems as well as consumables and services.
NuVasive (NUVA) Launches Pulse Integrated Technology Platform
by Zacks Equity Research
The launch of this system is in sync with NuVasive's (NUVA) endeavor to deliver end-to-end solutions that offer predictable clinical and economic outcomes in spine surgery.
Boston Scientific's Global Growth Robust Amid Currency Woe
by Zacks Equity Research
Boston Scientific (BSX) is currently pinning hopes on a stronger performance in China, backed by the recent approval of SYNERGY in the country.
Medtronic Releases Positive Results of LATERAL Clinical Trial
by Zacks Equity Research
Positive outcomes prove to be a major breakthrough for Medtronic (MDT) in the growing field of ventricular assist devices.
Varian (VAR) Installs ProBeam Compact in Thailand's Hospital
by Zacks Equity Research
Varian (VAR) gains from a slew of recent developments in its Proton Therapy platform.
Varian (VAR) to Boost Cancer Treatment With New Partnership
by Zacks Equity Research
Varian (VAR) expects to enhance cancer care with the new collaboration with IAEA, which is likely to drive Varian's core Oncology business.
ResMed (RMD) Rides on Strong SaaS Growth & New Product Suite
by Zacks Equity Research
ResMed's (RMD) new product menu and an array of strategies are likely to benefit from the sleep-disordered breathing market. This should further drive its short-term performance.
Integra Partners AI-Driven Data Analytics Firm in Wound Care
by Zacks Equity Research
Integra LifeSciences (IART) expects its partnership with Tissue Analytics to be perfectly strategic as the latter's software solutions automatically derive high quality data from clinical pictures.
Phibro Animal Sees Crucial Progress in ASF Vaccine Development
by Zacks Equity Research
The identification of a group of peptides and proteins is a remarkable step toward Phibro's (PAHC) development of a solution for ASF.
Fresenius Set for Global Expansion of Research Activities
by Zacks Equity Research
Fresenius Medical Care (FMS) aims to expand the scope of its clinical research activities through an integration move.
Illumina (ILMN) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Illumina (ILMN) gains from expansion of its product portfolio and strategic partnership.
CVS Health Banks on Aetna Prospects, Omnicare May Disappoint
by Zacks Equity Research
CVS Health's (CVS) Aetna integration synergies bode well for the stock.
Boston Scientific to Sell Bead Suit, Make Way for BTG Buyout
by Zacks Equity Research
The sale of oncology bead products by Boston Scientific (BSX) is expected to be among the last steps undertaken by the company to obtain Federal Trade Commission's approval for BTG buyout.
Here's Why CVS Health (CVS) Should Be in Your Portfolio
by Zacks Equity Research
Investors' trust continues to be high in CVS Health (CVS), thanks to strength in its PBM business.
Here's Why Chemed (CHE) Should Remain in Your Portfolio Now
by Zacks Equity Research
Investors' trust in Chemed (CHE) continues to be high, banking on its sturdy segmental performance.
Edwards Lifesciences Recalls Heart Device on Balloon Rupture
by Zacks Equity Research
Shares of Edwards Lifesciences (EW) decline post product recall news.
Smith & Nephew Acquires Atracsys, Expands Robotic Portfolio
by Zacks Equity Research
With Smith & Nephew's (SNN) buyout of Atracsys, the latter's fusionTrack 500 optical tracking camera will be a core enabling technology for the company's next-generation robotics platform.
Varian to Acquire Boston Scientific's Embolic Bead Products
by Zacks Equity Research
Varian (VAR) expects the buyout to prove accretive to its fiscal 2020 reported and adjusted earnings per share.
Myriad Genetics' Elevate 2020 Plan Holds Promise Amid Issues
by Zacks Equity Research
Myriad Genetics (MYGN) unveils an 'Elevate 2020' program that aims to generate $50 million in incremental operating income by fiscal 2020.
Medtronic's Titan Spine Buyout to Boost Spine Surgery Range
by Zacks Equity Research
Medtronic's (MDT) comprehensive biologics portfolio clubbed with Titan Spine's surface-enhanced titanium implants can enhance patient outcomes in spinal procedures.
Walgreens Gains on Strategic Deals, Margin Pressure Remains
by Zacks Equity Research
Walgreens Boots' (WBA) Retail Pharmacy USA division is witnessing comparable prescription growth and also benefiting from a strong retail prescription market.